The NRFC has made a $20 million investment in Omniscient Neurotechnology (Omniscient), an Australian neuroscience company that is a global leader in the emerging field of clinical connectomics.
Omniscient’s technology uses AI to generate highly detailed maps of the human brain from MRI scans, allowing neurosurgeons to personalise treatment plans based on patients’ brain maps rather than generalised anatomical diagrams.
NRFC funding will be used by Omniscient to further commercialise its proprietary AI platform Quicktome®, grow its data science team, and develop next-generation clinical applications for its technology.
About Omniscient Neurotechnology
Omniscient was founded in Sydney in 2019 and currently employs 16 people in Australia.
Its Quicktome platform has been approved by the U.S. Food and Drug Administration and is already in use at major hospitals and research institutions around the world.
Omniscient has a five-year plan to create a connectomics centre of excellence in Sydney as well as expand its footprint in the U.S.
Investment impact
Improving health and economic outcomes
Omniscient is a world leader in medical AI, and its technology has the potential to improve the lives of millions of people suffering from conditions such as depression, Alzheimer’s disease, schizophrenia, and stroke.
The NRFC’s investment in Omniscient will allow the company to further develop its Quicktome platform and expand it to more clinical settings around the world.
Commercialising Australian innovation
Omniscient’s ground-breaking technology was developed in Sydney by its co-founders Dr Michael Sughure and Dr Stephane Doyen. The NRFC’s investment is ensuring that life-changing medical AI continues to be pioneered in Australia.
Creating jobs
The NRFC’s investment will help Omniscient to create a connectomics centre of excellence in Sydney and expand its U.S. footprint. This will help to create over 40 new highly skilled jobs across AI, neuroscience, and product development.
Crowding-in finance
The NRFC is leading Omniscient’s Series D funding round alongside Australian venture fund OIF Ventures. Omniscient is expecting to raise up to $36 million in this funding round.